SEARCH:   Advanced

Blood, 1 November 2004, Vol. 104, No. 9, pp. 2704-2713. Prepublished online as a Blood First Edition Paper on July 6, 2004; DOI 10.1182/blood-2003-12-4319. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-12-4319v1 104/9/2704    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tang, Y. Articles by Deisseroth, A. Search for Related Content PubMed PubMed Citation Articles by Tang, Y. Articles by Deisseroth, A. Related Collections Immunobiology Neoplasia Immunotherapy Gene Therapy Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  GENE THERAPY Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens Yucheng Tang, Lixin Zhang, Jing Yuan, Hakan Akbulut, Jonathan Maynard, Phyllis-Jean Linton, and Albert Deisseroth From the Sidney Kimmel Cancer Center, San Diego, CA. Our goal in the present work was to characterize the multiple steps involved in overcoming the anergy that exists in tumor hosts to tumor-associated antigen (TAA). Our studies showed that the subcutaneous injection of the Ad-sig-TAA/ecdCD40L vector resulted in secretion of the TAA/ecdCD40L protein for at least 10 days from infected cells. Binding of the TAA/ecdCD40L protein to dendritic cells (DCs) resulted in the induction of CCR-7 chemokine receptor expression and cytokine release. This was followed by migration of the DCs to regional lymph nodes. Tetramer staining, enzyme-linked immunospot (ELISPOT) assay, and cytotoxicity assay all showed that the Ad-sig-TAA/ecdCD40L vector increased the levels of splenic CD8+ T cells specific for the 2 TAAs (human MUC1 [hMUC1] and HPV E7) tested. Vaccination with the Ad-sighMUC1/ecdCD40L vector suppressed the growth of hMUC1 antigen-positive tumor cells in 100% of the test mice that were previously anergic to the hMUC1 antigen. These data suggest that Ad-sig-TAA-ecd/ecdCD40L vector injections may be of value in treating the many epithelial malignancies in which TAA-like hMUC1 is overexpressed. (Blood. 2004;104:2704-2713) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Your Ad here: optimizing adenoviral vector-based vaccines H. Kim Lyerly Blood 2004 104: 2612-2613. [Full Text] [PDF] This article has been cited by other articles: Y. Tang, H. Akbulut, J. Maynard, L. Petersen, X. Fang, W.-W. Zhang, X. Xia, J. Koziol, P.-J. Linton, and A. Deisseroth Vector Prime/Protein Boost Vaccine That Overcomes Defects Acquired during Aging and Cancer J. Immunol., October 15, 2006; 177(8): 5697 - 5707. [Abstract] [Full Text] [PDF] H. Akbulut, Y. Tang, K. G. Akbulut, J. Maynard, L. Zhang, and A. Deisseroth Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer. Mol. Cancer Ther., August 1, 2006; 5(8): 1975 - 1985. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020